Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Axi-Cel Advances Signal Shifts Toward Earlier-Line Applications in LBCL

October 16th 2025

Taylor Brooks, MD, discusses the effects of CAR T-cell therapy on LBCL management and the efficacy of axi-cel for patients with relapsed/refractory LBCL.

Dr Visco on the Design of the FIL_V-RBAC Trial of RBAC Plus Venetoclax in High-Risk MCL

October 16th 2025

Carlo Visco, MD, discussed key design elements of the FIL_V-RBAC study of RBAC followed by venetoclax in older patients with high-risk MCL.

Dr Tarantino on the Role of Genomic Testing in HER2+ Breast Cancer

October 16th 2025

Paolo Tarantino, MD, PhD, discusses the role of genomic testing for guiding treatment decisions for patients with HER2-positive breast cancer.

Dr Randall on the Diagnostic Accuracy and Cost Effectiveness of MRI vs Ultrasound in STS

October 16th 2025

R. Lor Randall, MD, FACS, compares the diagnostic accuracy, recurrence detection rates, and cost effectiveness of MRI vs ultrasound STS surveillance.

Dr Gupta on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

October 15th 2025

Shilpa Gupta, MD, discusses the clinical effects of findings from the phase 3 EV-302/KEYNOTE-A39 trial in locally advanced/metastatic urothelial carcinoma.

Dr Le on the Prevalence of EGFR PACC Mutations in NSCLC

October 15th 2025

Xiuning Le, MD, PhD, discusses the prevalence of EGFR PACC mutations in NSCLC.

Dr Lou on the Rationale for Evaluating CISH Knockout TILs Using CRISPR-Cas9 Gene Editing in Metastatic GI Cancers

October 15th 2025

Emil Lou, MD, PhD, FACP, discusses the rationale for evaluating CISH knockout TILs using CRISPR-Cas9 gene editing in metastatic GI cancers.

Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma

October 15th 2025

Acalabrutinib plus lenalidomide and rituximab displayed activity and had a tolerable safety profile in first-line follicular lymphoma.

Expanding Radioligand Options Redefine mCRPC Management and Individualize Patient Care

October 15th 2025

Alicia Morgans, MD, MPH, discusses the role of radioligand therapies for mCRPC and the importance of shared decision-making in prostate cancer management.

Rucaparib Maintenance Therapy Displays Activity in Pretreated Recurrent/Metastatic Endometrial Cancer

October 15th 2025

Maintenance rucaparib showed efficacy in recurrent/metastatic endometrial cancer after the completion of first- or second-line chemotherapy.

64Cu-SAR-bisPSMA Bests SOC 68Ga-PSMA-11 PET/CT in Detecting PSMA-Positive Prostate Cancer Lesions

October 14th 2025

64Cu-SAR-bisPSMA displayed a higher detection rate of PSMA-positive prostate cancer lesions vs 68Ga-PSMA-11 PET/CT in patients with low PSA levels.

Tucatinib Plus Trastuzumab and Pertuzumab Maintenance Improves PFS in HER2+ Metastatic Breast Cancer

October 14th 2025

Combining tucatinib with trastuzumab and pertuzumab improved PFS as first-line maintenance in patients with HER2-positive metastatic breast cancer.

Dr Gerds on the Distinct Mechanisms of Action of Approved JAK Inhibitors for Myelofibrosis

October 14th 2025

Aaron T. Gerds, MD, MS, discusses the mechanisms of action of the 4 FDA-approved JAK inhibitors available for the treatment of patients with myelofibrosis.

Dr Mouhieddine on Ferritin and ALC As Markers of Bispecific Antibody Response in Myeloma

October 14th 2025

Tarek Mouhieddine, MD, discusses the use of ferritin and ALC as biomarkers of response to bispecific antibodies in relapsed/refractory multiple myeloma.

Abemaciclib Displays Efficacy, Tolerability in HIV-Associated and HIV-Negative Kaposi Sarcoma

October 13th 2025

Abemaciclib was safe and active for the treatment of patients with HIV-associated and -negative Kaposi sarcoma.

Dr Randall on the Benefits and Limitations of MRI in Soft Tissue Sarcoma Surveillance

October 9th 2025

R. Lor Randall, MD, FACS, discusses the current paradigm and future trajectory of imaging modalities for the surveillance of soft tissue sarcoma.

Dr Tarantino on the CompassHER2 pCR Trial of THP in HER2+ Breast Cancer

October 9th 2025

Paolo Tarantino, MD, PhD, discusses the design and background of the CompassHER2 pCR trial of THP in HER2-positive breast cancer.

Fruquintinib Represents Viable Later-Line Option for mCRC As Access Expands for Patients

October 9th 2025

Kanwal P.S. Raghav, MBBS, MD, discusses the role of fruquintinib for the treatment of patients with later-line colorectal cancer.

Eribulin Plus Pyrotinib Displays Efficacy in Trastuzumab-Resistant HER2+ Breast Cancer

October 9th 2025

Eribulin with pyrotinib was safe and active in patients with HER2-positive advanced breast cancer who were resistant to treatment with trastuzumab.

WTX-124 Nets FDA Fast Track Designation in Melanoma Following Immunotherapy

October 8th 2025

WTX-124 has received fast track designation from the FDA for locally advanced or metastatic cutaneous melanoma after standard-of-care immunotherapy.